Development and characterization of an αvβ6-specific diabody and a disulfide-stabilized αvβ6-specific cys-diabody.

[1]  R. Tavaré,et al.  Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation. , 2014, Protein engineering, design & selection : PEDS.

[2]  J. Cuzick,et al.  Altered Microenvironment Promotes Progression of Preinvasive Breast Cancer: Myoepithelial Expression of αvβ6 Integrin in DCIS Identifies High-risk Patients and Predicts Recurrence , 2013, Clinical Cancer Research.

[3]  T. Meyer,et al.  Generation and Characterization of a Diabody Targeting the αvβ6 Integrin , 2013, PloS one.

[4]  Sanjiv S Gambhir,et al.  18F-Fluorobenzoate–Labeled Cystine Knot Peptides for PET Imaging of Integrin αvβ6 , 2013, The Journal of Nuclear Medicine.

[5]  J. Tomlinson,et al.  An Engineered Cysteine-Modified Diabody for Imaging Activated Leukocyte Cell Adhesion Molecule (ALCAM)-Positive Tumors , 2012, Molecular Imaging and Biology.

[6]  M. Cooper,et al.  Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability. , 2012, Bioconjugate chemistry.

[7]  A. Wu,et al.  ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging , 2012, Tumor Biology.

[8]  V. Tolmachev,et al.  Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  Yin Zhang,et al.  Positron Emission Tomography Imaging of CD105 Expression with a 64Cu-Labeled Monoclonal Antibody: NOTA Is Superior to DOTA , 2011, PloS one.

[10]  W. Oyen,et al.  Immuno-PET of Cancer: A Revival of Antibody Imaging , 2011, The Journal of Nuclear Medicine.

[11]  H. Tseng,et al.  Microfluidic-Based 18F-Labeling of Biomolecules for Immuno–Positron Emission Tomography , 2011, Molecular imaging.

[12]  U. Haberkorn,et al.  ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: comparison of easy-to-label recombinant proteins for [68Ga]PET imaging of VEGF receptors in angiogenic vasculature. , 2010, Nuclear medicine and biology.

[13]  M. Robinson,et al.  Immuno-positron emission tomography in cancer models. , 2010, Seminars in nuclear medicine.

[14]  C. Anderson,et al.  Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. , 2009, Cancer Biotherapy and Radiopharmaceuticals.

[15]  C. Abbey,et al.  Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model. , 2009, Cancer research.

[16]  Anna M. Wu,et al.  Antibodies and Antimatter: The Resurgence of Immuno-PET , 2008, Journal of Nuclear Medicine.

[17]  A. Wu,et al.  Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2. , 2008, Bioconjugate chemistry.

[18]  A. Gown,et al.  Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. , 2008, Cancer research.

[19]  G. V. van Dongen,et al.  Immuno-PET: a navigator in monoclonal antibody development and applications. , 2007, The oncologist.

[20]  J. Sutcliffe,et al.  Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography. , 2007, Cancer research.

[21]  A. Gorter,et al.  Overexpression of the αvβ6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival , 2007 .

[22]  S. Gambhir,et al.  PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  M. Zalutsky,et al.  Synthesis of N-succinimidyl 4-[18F]fluorobenzoate, an agent for labeling proteins and peptides with 18F , 2006, Nature Protocols.

[24]  David Schrama,et al.  Antibody targeted drugs as cancer therapeutics , 2006, Nature Reviews Drug Discovery.

[25]  P. Hudson,et al.  Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.

[26]  Wenjun Guo,et al.  Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.

[27]  S. Goodman,et al.  Immunohistochemical screening for β6‐integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up‐regulation in pancreatic ductal adenocarcinomas in vivo and in vitro , 2004 .

[28]  K. Simon,et al.  Function-blocking Integrin αvβ6 Monoclonal Antibodies , 2004, Journal of Biological Chemistry.

[29]  G. Rice,et al.  αvβ6 Integrin-A Marker for the Malignant Potential of Epithelial Ovarian Cancer , 2002 .

[30]  B. Schmidt,et al.  Expression of integrin β6 enhances invasive behavior in oral squamous cell carcinoma , 2002 .

[31]  A. Kortt,et al.  Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. , 2001, Biomolecular engineering.

[32]  D. Sheppard,et al.  Expression of the αvβ6 Integrin Promotes Migration and Invasion in Squamous Carcinoma Cells , 2001 .

[33]  P. Speight,et al.  αvβ6integrin promotes invasion of squamous carcinoma cells through up‐regulation of matrix metalloproteinase‐9 , 2001 .

[34]  L E Williams,et al.  Numerical selection of optimal tumor imaging agents with application to engineered antibodies. , 2001, Cancer biotherapy & radiopharmaceuticals.

[35]  H R Hoogenboom,et al.  Design and application of diabodies, triabodies and tetrabodies for cancer targeting. , 2001, Journal of immunological methods.

[36]  A. Kortt,et al.  High avidity scFv multimers; diabodies and triabodies. , 1999, Journal of immunological methods.

[37]  P. Hudson,et al.  Recombinant antibody fragments. , 1998, Current opinion in biotechnology.

[38]  Zhongqi Zhang,et al.  A universal algorithm for fast and automated charge state deconvolution of electrospray mass-to-charge ratio spectra , 1998, Journal of the American Society for Mass Spectrometry.

[39]  L E Williams,et al.  Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. , 1996, Immunotechnology : an international journal of immunological engineering.

[40]  T Prospero,et al.  "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[41]  C. Alberini,et al.  Secretion of immunoglobulin M assembly intermediates in the presence of reducing agents , 1990, Nature.

[42]  W. Mcbride,et al.  The radiolabeling of proteins by the [18F]AlF method. , 2012, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[43]  Wenbin Zeng,et al.  Facile synthesis of N‐succinimidyl 4‐[18F]fluorobenzoate ([18F]SFB) for protein labeling , 2008 .

[44]  S. Gambhir,et al.  Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. , 2004, Protein engineering, design & selection : PEDS.